Clinical Trial Update: Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update showing safety and efficacy data for Natalizumab (Tysabri) in Russian participants with relapsing-remitting multiple sclerosis, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED